Overexpression of eIF-5A2 in mice causes accelerated organismal aging by increasing chromosome instability by Muhan Chen et al.
RESEARCH ARTICLE Open Access
Overexpression of eIF-5A2 in mice causes
accelerated organismal aging by increasing
chromosome instability
Muhan Chen1, Jian-Dong Huang2, Hong Kui Deng3, Suisui Dong1, Wen Deng4, Sze Lan Tsang2, Michael SY Huen2,
Leilei Chen1, Tong Zan3, Gui-Xia Zhu2 and Xin-Yuan Guan1*
Abstract
Background: Amplification of 3q26 is one of the most frequent genetic alterations in many human malignancies.
Recently, we isolated a novel oncogene eIF-5A2 within the 3q26 region. Functional study has demonstrated the
oncogenic role of eIF-5A2 in the initiation and progression of human cancers. In the present study, we aim to
investigate the physiological and pathological effect of eIF-5A2 in an eIF-5A2 transgenic mouse model.
Methods: An eIF-5A2 transgenic mouse model was generated using human eIF-5A2 cDNA. The eIF-5A2 transgenic
mice were characterized by histological and immunohistochemistry analyses. The aging phenotypes were further
characterized by wound healing, bone X-ray imaging and calcification analysis. Mouse embryo fibroblasts (MEF)
were isolated to further investigate molecular mechanism of eIF-5A2 in aging.
Results: Instead of resulting in spontaneous tumor formation, overexpression of eIF-5A2 accelerated the aging
process in adult transgenic mice. This included decreased growth rate and body weight, shortened life span,
kyphosis, osteoporosis, delay of wound healing and ossification. Investigation of the correlation between cellular
senescence and aging showed that cellular senescence is not required for the aging phenotypes in eIF-5A2 mice.
Interestingly, we found that activation of eIF-5A2 repressed p19 level and therefore destabilized p53 in transgenic
mouse embryo fibroblast (MEF) cells. This subsequently allowed for the accumulation of chromosomal instability,
such as errors in cell dividing during metaphase and anaphase. Additionally, a significantly increase in number of
aneuploidy cells (p < 0.05) resulted from an increase in the incidences of misaligned and lagging chromosomal
materials, anaphase bridges, and micronuclei in the transgenic mice.
Conclusion: These observations suggest that eIF-5A2 mouse models could accelerate organismal aging by increasing
chromosome instability.
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Background
It is believed that the process of malignant tumor is a
multiple-step process caused by the accumulation of
abnormal expression of oncogenes and tumor suppres-
sor genes. Therefore, the identification of commonly
amplified chromosomal region and corresponding over-
expressed oncogenes within the region is imperative
to understand the molecular mechanism of cancer
development. Amplification of chromosomal region
3q26 is frequently detected in solid tumors, including
ovarian [1], lung [2], esophageal [3], prostate [4], breast
[5], and nasopharyngeal cancers [6], suggesting that
3q26 contains an oncogene(s) related to the pathogen-
esis of human cancers. Using hybrid selection approach,
we identified a candidate oncogene, eukaryotic transla-
tion initiation factor 5A2 (eIF5-A2), from 3q26.2 [7,8].
The functions of eIF-5A2 are mainly revealed in cancer
initiation and progression. The tumorigenic ability of
eIF5-A2 has been demonstrated by several in vitro
evidences: eIF-5A2 stably transfected LO2 cells
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(immortalized human liver cell line) displayed increased
colony formation in soft agar and xenograph formation
in nude mice; reduction of eIF-5A2 in ovarian cancer
cell line UACC-1598 inhibits cell growth; and the onco-
genic ability of eIF5-A2 can be blocked by eIF-5A2 silen-
cing [7-9]. Previously, we showed that overexpression of
eIF-5A2 at the protein level was significantly associated
with the advanced stages of ovarian cancer [8]. Similarly,
Marchet et al. recently reported that overexpression of
eIF-5A2 is associated with a higher risk of lymph node
metastasis in human gastric adenocarcinomas [10].
Recently, Zender et al. identified that eIF-5A2 is ampli-
fied in human cancer using representational oligonu-
cleotide microarray analysis (ROMA), and is required
for proliferation of XPO4-deficient tumor cells and pro-
motes hepatocellular carcinoma in mice [11]. However,
the in vivo function of eIF-5A2 is still not clear.
To further investigate the functions of the eIF-5A2 gene
per se, we generated eIF-5A2 transgenic mice. Unexpect-
edly, the eIF-5A2 transgenic mice exhibit accelerated orga-
nismal aging phenotypes instead of forming spontaneous
tumors. Cancer is assumed to be a disease of accumulated
aged cells because of the close link between incidence of
the cancer and the aging process. For decades, age has been
regarded as the largest risk factor associated with the cancer
initiation, which is supported by cancer incidence rising
exponentially with age [12,13]. Mechanistically, genomic
instability in somatic cells has been implicated as one of the
major stochastic causes of aging [14-16]. Furthermore, cel-
lular senescence, a potential in vitro counterpart of organis-
mal aging, was demonstrated by several recent studies as a
barrier to tumorigenesis, and contributes to the cytotoxicity
of certain anticancer agents [17]. However, it is not clear
whether aging functions the same way as cellular senes-
cence to suppress tumor initiation in vivo. Also, there is no
direct evidence to elucidate the functional contribution of
senescent cells towards the onset of aging.
In this study, we found that eIF-5A2 overexpression
triggers premature aging in multiple organs of the trans-
genic mice. We further demonstrated that supraphysio-
logical expression of eIF-5A2 repressed p19 expression
and therefore impaired p53 levels. This allowed for the
accumulation of chromosomal instability, which ulti-
mately led to organismal aging. To our knowledge, this
study revealed for the first time a role of putative onco-
genic eIF-5A2 in accelerating the aging process. More-
over, the accelerated aging process shows tumor
suppression effects in vivo, and cellular senescence is
not required for this single genetic change caused aging.
Methods
Generation of eIF-5A2 transgenic mice
A 462 bp human eIF-5A2 cDNA fragment was cloned
into the pCAGGS vector. The linearized constructs were
injected into one-cell-stage F1 mouse embryos, which
were transplanted into pseudo-pregnant females. All
resulting pups were screened for the presence of the
transgene using a pair of primers from the vector
sequence and a pair of primers from the human eIF-5A2
gene. For studies relying on timed pregnancies, mating
pairs were established and mice were monitored daily
for vaginal plugs, the presence of which would indicate
0.5 days post-copulation. Animal experimentation was
done in accordance with the guidelines of the University
of Hong Kong regarding the care and use of laboratory
animals.
Western and Northern blot analysis
For Western blot analysis, Protein lysates were prepared
with RIPA buffer (1 × PBS, 1% Nonidet P40, 0.5% sodium
deoxycholate, 0.1% SDS and protease inhibitor cocktail).
About 10 μg of lysate was separated by SDS-polyacryla-
mide gel electrophoresis, transferred to a PVDF Hybond-
P membrane (Amersham Pharmacia Biotechnology, Pis-
cataway, NJ), and detected by antibodies for eIF-5A2 (a
mouse monoclonal antibody raised against the 54 resi-
dues of eIF-5A2), p53 (Zymed, San Francisco, CA), p21
(Upstate, Temecula, CA), p19 (Upstate, Lake Placid, NY),
CDK4 (Cell Signaling Technology, Beverley, MA), and g-
tubulin (Sigma, St. Louis, MO). For Northern blot analy-
sis, total cellular RNA was prepared using the TRIzol/
chloroform method. Twenty microgram of RNA was size
fractionated, transferred to a nylon membrane, and
hybridized with a 32P-labeled human eIF-5A2 specific
probe as described previously[7,8].
Histological analysis, immunohistochemistry, senescence
and BrdU incorporation assay
Fresh mouse tissues were fixed in 4% cold paraformalde-
hyde in PBS, processed into serial paraffin sections, and
stained with Mayer’s hematoxylin-eosin staining. Immu-
nohistochemistry (IHC) was performed using the follow-
ing antibodies: eIF-5A2 (1:500 dilution), PCNA (1:500
dilution, Santa Cruz Biotechnology, Santa Cruz, CA).
Internal standardization was achieved by comparing
only images stained with the same antibodies in the
same experiment, captured with identical parameters,
and scaled and displayed identically. For b-galactosidase
staining, MEF cells were stained for senescence-asso-
ciated acidic b-galactosidase activity according to the
manufacturer’s protocol (Cell Signaling Technology,
Beverley, MA). BrdU (100 mg/g of body weight) was
injected i.p. into pregnant females. Then the animals
were killed 2 h after injection and the mouse tissues or
embryos were fixed in 4% paraformaldehyde at 4°C
overnight. Then the sections were processed for stained
with BrdU staining kit (ZYMED) according to the man-
ufacturer’s protocol.
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Wound healing experiments
4-month old mice were anaesthetized with methoxy-
fluorane, and the dorsum was shaved and cleaned with
alcohol. Three equidistant 1-cm full-thickness incisional
wounds were made through the skin and panniculus
carnosus muscle. Wounds were measured at days 1, 2, 3
and 4 post-wounding, and wounded skin specimens
were collected and bisected for histology at day 4 post-
wounding.
Bone X-ray imaging and calcification analysis
Individual mice were subjected to an X-ray imager for
the detection of kyphosis and osteoporosis. In brief, mice
were anaesthetized with 2% isofluorane and images were
taken by a 600P X-ray mammogram machine (General
Electric Co., Albuquerque, NM) with a dose of 15 kV for
100 sec. For calcification analysis, embryos were eviscer-
ated and the skin was removed. The embryos were fixed
in 95% ethanol and stained in Alcian blue solution and
Alizarin red solution overnight as described previously
[18].
Isolation of mouse embryo fibroblast (MEF) cells
E13.5 embryos were digested at 37°C for 10 min in 0.2%
trypsin (Sigma, St. Louis, MO) in PBS (pH 7.4). The cell
suspension was cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS at 37°C.
For cell proliferation analysis, 5 × 104 wild-type and eIF-
5A2 transgenic MEF cells were plated on 6-well plates
and cell numbers were counted every day for up to 6
days. For flowcytometry test, cells were fixed in 70%
ethanol, stained with propidium iodide, and analyzed by
flow cytometer.
Cytogenetic analysis, FISH and SKY
Metaphase spreads were prepared from either cultured
MEF cells or bone marrow lymphocytes. Metaphases were
harvested from cultured MEFs by Colcemid treatment
(0.03 μg/ml) for 3 hr or from bone marrow lymphocytes
in tested mice by colchincine treatment (3 mg/kg, intra-
peritoneal injection). Metaphase spreads were stained by
standard trypsin-Giemsa banding method and analyzed
under microscope as described previously [7].
For fluorescence in situ hybridization (FISH) analysis,
the whole transgene construct was used as a probe, which
was labeled with Spectrum Red-dUTP by nick translation
(Life Technologies, Inc.). The labeled probe was then
hybridized to prebanded wild-type or eIF-5A2 transgenic
MEF metaphase chromosomes as described previously [7].
Spectral karyotyping (SKY) was performed using a
SKY probe (Applied Spectral Imaging, Migdal Ha’Emek,
Israel) as described previously [19,20]. The signal detec-
tion followed the recommendations of the SKY probe
manufacturer. SKY image capturing and karyotyping
were performed using the SkyVision Imaging System
equipped with a Zeiss Axioplan 2 fluorescence
microscope.
Telomerase activity assay
The telomere repeat amplification protocol (TRAP) assay
was performed using the TRAPEZE kit (Invitrogen, New
York, NY) following the manufacturer’s protocol. Except
for negative control (lysis buffer), 0.05 μg protein was
used for each PCR, which was run for 33 cycles.
Statistical analysis
Statistical analysis was performed using the SPSS soft-
ware (SPSS Standard version 8.0). Significance of differ-
ence was analyzed using Student’s t tests. A significant
difference was considered when the p value was less
than 0.05.
Results
Generation of eIF-5A2 transgenic mouse lines
To characterize the role of eIF-5A2 in vivo, we gener-
ated transgenic mouse lines overexpressing human eIF-
5A2 ubiquitously. Pronuclear injection of the pCAGGS-
eIF-5A2 construct resulted in the generation of three
founder mice, as identified by genomic Southern blot
analysis and PCR (Figure 1A). To confirm the single
integration event, an eIF-5A2 probe was used to hybri-
dize to the metaphase spreads from bone marrow lym-
phocytes by fluorescence in situ hybridization (FISH).
The transgene was mapped to one chromosome site in
line 11 (Figure 1B). All the founders were able to trans-
mit the transgene to their offspring in the expected
Mendelian ratio. Three lines were expanded, and the
expression of the transgene was confirmed in two out of
three founder lines (10 and 11). Expression of eIF-5A2
at the RNA level was detected by RT-PCR and Northern
blot hybridization using liver and testis tissues (Figure
1C). Also, EIF-5A2 protein expression was demonstrated
by immunohistochemistry (IHC) and Western blot ana-
lysis (Figure 1D) in multiple organs. Of note, no differ-
ence was observed in the expression of murine
endogenous eIF-5A2 among the founders and wild-type
controls. To ensure that the observed phenotypes were
not a result of genomic insertion positional effects, we
performed all experiments with both transgenic lines
and obtained similar results for both lines. Expression of
transgene eIF-5A2 in trnasgenic mice could be detected
in all tested tissues by RT-PCR (Figure 1E).
Characterization of eIF5-A2 transgenic mice
To determine the effects of eIF-5A2 on mouse develop-
ment, protein expression in13.5-day embryos and 12-
week old mice was studied. On embryonic day 13.5,
expression of eIF-5A2 was detected in the developing
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brain, liver and cartilage (Figure 2). At 12-week of age,
EIF-5A2 protein expression was detected in all the
tested adult tissues, including brain, lung, heart, liver,
kidney, spleen, testis, uterus and ovary (sure 3A). Histo-
logical analysis showed that the morphologies of all
tested tissues in eIF-5A2 transgenic embryos/mice were
indistinguishable from their wild-type counterparts. To
test the effects of eIF-5A2 overexpression on cell prolif-
eration, BrdU incorporation assay and proliferating cell
nuclear antigen (PCNA) immunostaining was applied to
measure the proportion of cells in S phase in E13.5
embryos and12-week-old mice, respectively. However,
the frequencies of BrdU positive cells in transgenic and
wild-type embryos (56.3 ± 7.81 vs. 52.73 ± 9.14, respec-
tively; p > 0.05) and PCNA positive cell percentages in
transgenic and wild-type mice (46.2 ± 10.98 vs. 37.87 ±
10.44, respectively; p > 0.05) were comparable (Figure 2
and 3A).
No spontaneous tumor formation was observed in eIF-
5A2 transgenic mice (n = 452) during a period of 3 years.
Alcohol intoxication, an efficient way to induce liver
tumorigenesis in cancer-prone rodents [21], was used to
induce liver lesions in 12-week-old eIF-5A2 transgenic
mice (n = 20) and wild-type littermates (n = 12). After 13
weeks of alcohol treatment, livers of transgenic and wild-
type mice were harvested and examined by histologists.
No visible liver tumors or precancerous lesions were
detected in all of the tested animals (Figure 3B). This
suggests that eIF-5A2 overexpression alone does not
increase the susceptibility of cancer onset in mice.
Exhibition of accelerated aging phenotypes in eIF-5A2
transgenic mice
eIF-5A2 transgenic mice were indistinguishable from
their wild-type siblings at birth. However, phenotypes of
transgenic mice and wild-type littermates could be
Figure 1 Generation of eIF-5A2 transgenic mice. (A) Three eIF-5A2 transgenic mouse founders (mouse No.: 10, 11, and 89) and their offspring
(166-169) were determined by PCR. One mouse without eIF-5A2 transgene (No. 9) was used as negative control. Mouse fibroblast cell line NIH 3T3
and eIF-5A2 transgenic construct was used as negative (-) and positive (+) controls. (B) The transgene eIF-5A2 was mapped to one mouse chromosome
site in line 11 by FISH. The metaphase spread was prepared from bone marrow lymphocyte. Arrow indicates the hybridization signals of eIF-5A2. (C)
Expression of eIF-5A2 in transgenic mice was confirmed by Northern blot analysis. A human eIF-5A2 cDNA probe was used and it did not detect the
endogenous eIF-5A2 mRNA in both wild-type and transgenic mice. (D) Western blot showed the overexpression of human eIF-5A2 in transgenic mice
using liver lysates. The lower bands (17dD) were eIF-5A2 and the upper bands were shifted eIF-5A2 bands caused by posttranslational hypusination.
(E) Expression of transgene eIF-5A2 in various tissues of transgenic mouse was detected by RT-PCR using a pair of human-specific primers.
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distinguished from postnatal week 3 according to body
size and weight. From 3 weeks of age, the growth rate
of transgenic mice was significantly reduced (about 20-
40%, P < 0.05, Student’s t tests) compared with wild-
type controls (Figure 4A). At 5 months of age, the body
weights of transgenic male mice (n = 11) and wild-type
male littermates (n = 8) were compared, and we found
the mean body weight of wild-type mice (57 ± 3.08 g)
was significantly higher than that of transgenic litter-
mates (37.1 ± 4.83 g, p < 0.05, Student’s t tests) (Figure
4B). Strikingly, most of the transgenic mice died at 7-9
months without any apparent causes of death or visible
Figure 2 Tissue distribution of transgenic eIF-5A2 protein and BrdU incorporation analysis of day 13.5 embryos. Expression of eIF-5A2
in developing liver, cartilage and neuroepithilium from transgenic and wild-type embryos (left) was detected by IHC (magnification, 400 ×). BrdU
incorporation assay (right) was used to compare the proliferation rates between transgenic and wild-type embryos. No significant difference was
observed in the percentage of BrdU positive cells between transgenic (56.3 ± 7.81) and wild-type embryos (52.73 ± 9.14, p > 0.05).
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changes observed by autopsy. The average lifespan of
eIF-5A2 mice is 8 months (Figure 4C).
Skin aging phenotypes in eIF-5A2 mice
Reduction of the capacity to respond to stresses such as
wound healing is often associated with human aging
[22]. Wound healing ability was compared between eIF-
5A2 transgenic mice and their wild-type siblings. We
found that wound healing was significantly delayed (p <
0.05, Student’s t tests) in transgenic mice compared
with their wild-type littermates (Figure 4D). Histological
analysis showed that the ability of re-epithelialization in
the edges of the wound was remarkably reduced in
transgenic mice compared to their wild-type controls
(Figure 4E). In addition, chronic skin lesions frequently
occurred in eIF-5A2 transgenic mice due to the unheal-
ing wounds or scratches (Figure 4F).
Skeletal degeneration in eIF-5A2 transgenic mice
Radiographs were taken to examine for potential skeletal
degeneration in eIF-5A2 transgenic mice (n = 6) and
their wild-type siblings (n = 5) at 24 weeks of age. Almost
Figure 3 eIF-5A2 expression, cell proliferation and histopathological analysis of 12-week-old mice (magnification, 400 ×). (A) Top panel,
eIF-5A2 immunostaining of liver and heart from transgenic and wild-type mice. Middle panel, proliferation was measured by using PCNA
immunostaining and the percentage of PCNA positive cells in transgenic mice (46.2 ± 10.98) was comparable to that in wild-type littermates
(37.87 ± 10.44, p > 0.05). Bottom panel, haematoxylin and eosin (H&E) staining of adult liver and heart tissues. (B) H&E staining of the transgenic
and wild-type livers after 12-week alcohol treatment.
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all the eIF-5A2 transgenic mice showed varying severity
of kyphosis at 24-week of age (Figure 5A). In addition,
the transgenic mice exhibited severe osteoporosis by
radiographic analysis compared with their wild-type sib-
lings (Figure 5B). We also stained the whole mouse skele-
tons with Alcian blue and Alizarin red to look at bone
and cartilage. Interestingly, we found that 2-week-old
transgenic mice showed several signs of delay of ossifica-
tion. Compared to their wild-type siblings, transgenic
pups had wide fontanelle and cranial sutures (Figure 5C
and 5D). In the hind limb, clear ossification of the patella
at the knee joint was observed in wild-type mice, but not
in transgenic mice (Figure 5E). These data suggest that
eIF-5A2 overexpression impairs ossification during
Figure 4 Aging-related phenotypes in eIF5A2 transgenic mice. (A) Cumulative plot of body weight versus age of male eIF-5A2 transgenic
mice (n = 11) and their wild-type siblings (n = 8). * P < 0.05. (B) Quantification of the mean body weight of 5-month-old male eIF-5A2
transgenic mice and wild-type littermates is shown in the left (p < 0.05), and the representative image of a 24-week-old transgenic mouse and
wild-type sibling was shown in the right. The body size of the transgenic mouse was significantly smaller than its wild-type sibling (P < 0.05). (C)
Kaplan-Meier survival curve of male transgenic mice (n = 29, red line) and wild-type controls (n = 35, blue line). (D) Comparison of wound
healing rates between 4-month-old eIF5A2 transgenic mice (15 wounds in 5 transgenic mice) and their wild-type siblings (12 wounds in 4 mice).
* P < 0.05. (E) Representative HE-stained section at day 4 post-wounding in an eIF-5A2 transgenic mouse (left) and its wild-type sibling (right).
The ability of re-epithelialization in the edges of wound was remarkably reduced in the transgenic mouse compared with its wild-type control
(indicated by arrows). (F) Chronic skin lesions in eIF-5A2 transgenic mice (indicated by arrows).
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Figure 5 Skeletal aging phenotypes in eIF-5A2 transgenic mice. (A) X-ray radiograph was used to examine skeletal changes in 24-week-old
eIF-5A2 transgenic mouse (upper) and their wild-type sibling (lower). Kyphosis was observed in eIF5A2 mouse (indicated by an arrow). (B)
Representative radiograph of the density of femur bone in an eIF-5A2 transgenic mouse (24-week-old) and a wild-type mouse. (C, D) Alcian blue
and Alizarin red staining of skulls from a 2-week-old transgenic mouse (upper) and its wild-type sibling (lower). A wider cranial sutures (C) and
fontanelle (D) were observed in transgenic pup (indicated by arrows). (E) Representative skeletal staining of hind limb in a 2-week-old transgenic
mouse (upper) and its wild-type sibling (lower). A clear ossification of patella was observed in the knee joint of wild-type mouse but not in the
transgenic mouse (indicated by arrows).
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development and contributes to osteoporosis and spine
degeneration in adulthood.
eIF-5A2 activation is insufficient for triggering cellular
senescence
Cellular senescence can be triggered by oncogene activa-
tion and agents that damage DNA or alter chromatin
structure [13,17]. Given our observation of organismal
aging in eIF-5A2 mice, we further investigated whether
cellular senescence exists under these circumstances.
Therefore, MEFs from eIF-5A2 transgenic mice and their
wild-type littermates were characterized. eIF-5A2 MEFs
were morphologically indistinguishable from the wild-
type counterparts at both early and late passages. The
activity of senescence associated b-galactosidase (SA-b-
gal), a cellular index of senescence, was eximined and no
difference was found between eIF-5A2 transgenic and
wild-type MEFs (Figure 6A). We also stained the cryostat
sections of skin, testis and liver, and did not detect any
SA-b-gal positive cells in vivo (not shown).
The p53 tumor suppressor pathway in senescence has
been well studied and serves as a critical player that med-
iates both replicative and oncogene-induced senescence.
Senescence plays an important role in protecting the
tumorous transformation of a living cell by oncogene acti-
vation via up-regulation of p53, p21 and p19 [23,24]. We
examined p53 levels and found a striking reduction of p53
at steady state (Figure 6B). Consequently, p53 transcrip-
tionally down-regulated its downstream target p21Cip1 and
indeed we found less p21Cip1 in eIF-5A2 MEFs. p19Arf
interferes with p53 negative regulator Mdm2 and therefore
induces and stabilizes p53 [25,26]. It has been reported
that the absent of p19 can enhance Mdm2’s ability to
down-regulate p53 during stress. We found a reduction of
p19 at the protein level in eIF-5A2 MEFs, suggesting that
eIF-5A2 activation serves as oncogenic stressor and thus
repressing p19 (Figure 6B). Subsequently, CDK4, the
down stream cell cycle molecule of p19 inhibitor, was up-
regulated in transgenic MEFs (Figure 6B), suggesting that
in vitro overexperssion of eIF-5A2 contributes to onco-
genic transformation, but does not drive the onset of cellu-
lar senescence.
Activation of eIF-5A2 caused partial transformation in
MEFs
Due to the massive overexpression of eIF-5A2 and
reduced levels of p53 in transgenic MEFs, we wondered
whether these together would favor cell proliferation.
Therefore, firstly transgenic and wild-type MEFs were
continuously passaged and monitored the replicative
capability. Both MEFs proliferated normally until pas-
sage 4 and the proliferation declined during later pas-
sages (passage 5 and 6) (Figure 6C). Next we used an
XTT assay to compare cell growth rates between eIF-
5A2 transgenic MEFs and wild-type MEFs. The cell pro-
liferating capability of transgenic MEFs was similar to
that of wild-type MEFs when fed with 10% serum
(Figure 6D). However, eIF-5A2 transgenic MEFs grew
significantly faster than wild-type MEFs in low-serum
(1%) conditions (p < 0.05, Figure 6E).
Telomerase has been detected in human cancer cells
and is more active in transformed cells than in normal
cells. This provides a selective growth advantage in trans-
formed cells. Given the facts that the activation of eIF-5A2
and down-regulation of tumor suppressors p19 and p53,
we hypothesized that eIF-5A2 MEFs could have increased
telomerase activity. We used a telomere repeat amplifica-
tion assay (TRAP) to compare the telomerase activities
between transgenic and wild-type MEFs. Interestingly,
6 out of 8 (75%) tested transgenic MEFs displayed
increased telomerase activity compared to 7 wild-type
controls (Figure 6F). Taken together, in in vitro culture we
obtained typical, at least partial, phenotypes similar to
transformed cells in transgenic MEFs overexpressing eIF-
5A2, which is consistent with our previous results [7,8].
Chromosomal instability in eIF-5A2 transgenic mice
Considering the role of p53 in maintenance of genetic
stability and its down-regulation in eIF-5A2 transgenic
mice, the correlation of eIF-5A2 expression and chromo-
somal instability was investigated. Metaphases from
MEFs and adult mouse bone marrow were cytogeneti-
cally characterized and compared between eIF-5A2 trans-
genic mice and their wild-type littermates. Karyotyping
analysis showed that the frequency of aneuploidy cells
was significantly higher in transgenic MEFs (18.5%, n =
200) than that in wild-type MEFs (4.5%, n = 200, p <
0.05). In adult mouse bone marrow cells, the frequency
of aneuploidy cells was significantly higher in transgenic
mice (11.5%, n = 200) than that in wild-type mice (3%, n
= 200, p < 0.05). Spectral karyotyping (SKY) analysis also
found an increased number of aneuploidy cells in adult
transgenic mice (16/100 metaphases) compared to wild-
type controls (6/100 metaphases) (Figure 7A).
The dividing MEF nuclei from both eIF-5A2 transgenic
mice and their wild-type littermates were also compared.
We found a significant increase in misaligned chromoso-
mal material in transgenic MEFs (3.1%, n = 1,000) com-
pared to wild-type controls (1.2%, n = 1,000, p<0.05)
(Figure 7B). Lagging chromosomal material, in the form
of an anaphase bridge (Figure 7B), was detected in 4.1%
(n = 1,000) of transgenic MEFs, but not in wild-type
MEFs. In addition, the detection of micronuclei after
mitosis was significantly higher in eIF-5A2 transgenic
mice (5.6%, n = 1,000) than in the wild-type controls
(2.2%, n = 1,000; p < 0.001, Figure 7C and 7D).
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Figure 6 Characterization of the eIF-5A2 transgenic MEF cells. (A) Senescence associated b-galactosidase staining in transgenic and wild-
type MEFs. No difference was observed between these two MEFs. (B) Western blot analysis of lysates from transgenic and wild-type MEFs
showed activation of eIF-5A2 repressed p19 level and therefore destabilized p53 and consequently repressed p21 in transgenic MEFs. (C) The
replication capacity of both MEFs were measured by seeding 1 × 104 cells into one well of 6-well plate and counted every 3 days. Both wild-
type and transgenic MEFs proliferated normally until passage 4 and proliferation capability declined during later passages (p5 and p6). (D, E) The
comparison of cell growth curves of transgenic and wild-type MEFs in 10% serum (D) and 1% serum (E). The cell growth rate was significantly
higher in transgenic MEFs than in wild-type MEFs (p < 0.05). (F) Increased telomerase activity was detected in eIF-5A2 transgenic mice compared
with their wild-type siblings. Protein extracted from HeLa cells was included as positive (+). A 36-bp internal standard was used as a control (IC)
in the assay: the bands were weaker in samples with excessively high telomerase activity because amplification of the TRAP products and the IC
bands were semicompetitive.
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Discussion
Our studies have identified eIF-5A2 as a single genetic
change involved in accelerating the aging process in
mice. Overexpression of eIF-5A2 results in aging pheno-
types in multiple organs in vivo, but is insufficient for
triggering cellular senescence. We provide here the
mammalian genetic evidence for the notion that orga-
nismal aging is not always linked to cellular senescence.
A key finding in our study is that activation of onco-
gene eIF-5A2 represses p19 levels and impairs its stabili-
zation of p53. Consequently, p53 transcriptionally
down-regulates p21Cip1 and therefore increases CDK4 in
response to p19 inhibition. However, these eIF-5A2
mediated pathway alterations function very differentially
in in vivo and in vitro contexts. In vivo, down-regulated
p19, p53 and p21 and up-regulated CDK4 promote cell
proliferation and increase telomere activity, which
belong to oncogenic transformation category. Conse-
quently, we observed partial transformation of eIF-5A2
MEFs, but not oncogene activation induced cellular
senescence. In the mouse, the activation of eIF-5A2 and
subsequent alteration of the p19-p53-p21 pathway, leads
to accelerated aging phenotypes. This confirms again
the fate of oncogene activation is context dependent.
The activation of eIF-5A2 alone in an in vitro system
shows a mild transformation capability and is insuffi-
cient to trigger the senescence response. While in the
intact mice context, the stress of eIF-5A2 activation
causes whole body responses and navigates to acceler-
ated aging to suppress tumorigenesis in vivo. As a result,
Figure 7 Chromosome instability in eIF-5A2 transgenic mice. (A) Representative SKY images (left) and reversed DAPI stain (right) of bone
marrow metaphase spreads from wild-type and transgenic mice. (B, C) Detection of hallmarks of chromosomal instability in eIF-5A2 transgenic
MEFs, including misaligned chromosomes separated from the metaphase plate (a’), lagging chromosomes in anaphase (b’ and c’), and
micronuclei in interphase cells (C). (D) Quantification of the incidence of the micronuclei, misaligned and lagging chromosomes.
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there is no spontaneous tumor formation in eIF-5A2
mice, and they are not cancer-prone, and they do not
respond to cancer reagents.
Notably, the p19 mediated impairment of p53, allowing
the accumulation of numerical genomic instability, was
revealed in both MEFs and mice. Human and mouse
models of accelerated aging frequently involve alterations
in genome maintenance mechanisms [21]. p53 plays a
critical role in cell cycle regulation and the maintenance
of genetic stability, which is associated with its function
in DNA damage reparation. Genomic instability has been
implicated as a major causal factor in early onset of the
aging phenotype, which was observed in mtr-/- mice and
Ku80 null mice [27,28]. Therefore, we hypothesized that
the molecular mechanism of eIF-5A2 in aging is asso-
ciated with p53-dependent chromosomal instability. The
data we collected from both in vivo and in vitro studies
showed a variety of chromosomal instability, including
higher incidences of unaligned and/or misaligned chro-
mosomal materials, anaphase bridges, and micronuclei.
They contribute to differential fates of either aging or
transformation depending on the different contexts, con-
firming the curial role of genomic instability in both
tumorigenesis and aging.
eIF-5A2 was originally identified as a proto-oncogene
whose overexpression leads to cancerous transformation
of hepatocellular carcinoma cell lines, and contributes to
cancer progression and metastasis. However, no sponta-
neous tumors were detected in transgenic mice overex-
pressing eIF-5A2. One possible explanation could be the
life span of the eIF-5A2 transgenic mouse is too short to
allow for the accumulation of extra genetic changes, and
defeat aging phenotypes, to form a detectable tumor. In
conclusion, we found that activation of eIF-5A2 causes
p53-mediated genomic instability and accelerates the
aging phenotype in multiple tissues in mice. This finding
provides more insight into the mechanism of accelerated
aging caused by oncogene activation in vivo.
Our study also revealed that cellular senescence is not
required for the organismal aging process. Cellular
senescence was considered as a potential counterpart of
organismal aging under certain circumstances [29-31].
Senescent cells have typical physiological changes,
including large and flat morphology, higher acidic b-
galactosidase enzymatic activity and profound growth
defects. The growth arrest of cellular senescence is actu-
ally a tumor suppressor mechanism to resist tumorigen-
esis via shortening the longevity of cells and preventing
cell proliferation. In addition, senescences often down-
regulate extracellular matrix production and upregulate
inflammatory cytokines to modulate the microenviro-
ment or immune response [13]. Although we observed
striking aging phenotypes in eIF-5A2 mice, there is no
evidence that the aging effect of eIF-5A2 is associated
with cellular senescence. Our model demonstrates that
cellular senescence is not required for the initiation of
eIF-5A2 mediated organismal aging. In another words,
organismal aging is not necessarily the consequence of
the accumulated senescent cells. This type of separation
of cellular senescence and organism aging can be cell
type and context dependent.
Conclusions
In the past several decades, age has been regarded as the
largest risk factor tightly linked to the initiation of cancer.
Cellular senescence, a potential in vitro counterpart of
organismal aging, contributes to the cytotoxicity of cer-
tain anticancer agents. Here, we reveal for the first time a
role of putative oncogenic eIF-5A2 in accelerating the
aging process by increasing chromosome instability, and
cellular senescence is not required for the aging pheno-
types in eIF-5A2 mice. Thus, we conclude that organis-
mal aging is not necessarily the consequence of the
accumulated senescent cells. This type of separation of
cellular senescence and organism aging can be cell type
and context dependent.
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